BiBLDR: Bidirectional Behavior Learning for Drug Repositioning

• URL: http://arxiv.org/abs/2505.23861v1
• Date: Thu, 29 May 2025 08:20:15 GMT
• Title: BiBLDR: Bidirectional Behavior Learning for Drug Repositioning
• Authors: Renye Zhang, Mengyun Yang, Qichang Zhao, Jianxin Wang,
• Abstract summary: Drug repositioning aims to identify potential new indications for existing drugs to reduce the time and financial costs associated with developing new drugs.<n>We propose a bidirectional behavior learning strategy for drug repositioning, known as BiBLDR.<n>This innovative framework redefines drug repositioning as a behavior sequential learning task to capture drug-disease interaction patterns.
• Score: 6.8413537951016306
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Drug repositioning aims to identify potential new indications for existing drugs to reduce the time and financial costs associated with developing new drugs. Most existing deep learning-based drug repositioning methods predominantly utilize graph-based representations. However, graph-based drug repositioning methods struggle to perform effective inference in cold-start scenarios involving novel drugs because of the lack of association information with the diseases. Unlike traditional graph-based approaches, we propose a bidirectional behavior learning strategy for drug repositioning, known as BiBLDR. This innovative framework redefines drug repositioning as a behavior sequential learning task to capture drug-disease interaction patterns. First, we construct bidirectional behavioral sequences based on drug and disease sides. The consideration of bidirectional information ensures a more meticulous and rigorous characterization of the behavioral sequences. Subsequently, we propose a two-stage strategy for drug repositioning. In the first stage, we construct prototype spaces to characterize the representational attributes of drugs and diseases. In the second stage, these refined prototypes and bidirectional behavior sequence data are leveraged to predict potential drug-disease associations. Based on this learning approach, the model can more robustly and precisely capture the interactive relationships between drug and disease features from bidirectional behavioral sequences. Extensive experiments demonstrate that our method achieves state-of-the-art performance on benchmark datasets. Meanwhile, BiBLDR demonstrates significantly superior performance compared to previous methods in cold-start scenarios. Our code is published in https://github.com/Renyeeah/BiBLDR.

Related papers

• Learning to Describe for Predicting Zero-shot Drug-Drug Interactions [54.172575323610175]
  Adverse drug-drug interactions can compromise the effectiveness of concurrent drug administration. Traditional computational methods for DDI prediction may fail to capture interactions for new drugs due to the lack of knowledge. We propose TextDDI with a language model-based DDI predictor and a reinforcement learning(RL)-based information selector.
  arXiv  Detail & Related papers  (2024-03-13T09:42:46Z)
• Relation-aware graph structure embedding with co-contrastive learning for drug-drug interaction prediction [4.639653766590366]
  We propose a novel DDI prediction method based on relation-aware graph structure embedding with co-contrastive learning, RaGSECo. The proposed RaGSECo constructs two heterogeneous drug graphs: a multi-relational DDI graph and a multi-attribute drug-drug similarity (DDS) graph. We present a novel co-contrastive learning module to learn drug-pairs (DPs) representations.
  arXiv  Detail & Related papers  (2023-07-04T06:41:50Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• Distributed representations of graphs for drug pair scoring [4.277733268268646]
  We study the practicality and usefulness of incorporating distributed representations of graphs into models within the context of drug pair scoring. We present a methodology for learning and incorporating distributed representations of graphs within a unified framework for drug pair scoring. We empirically show that the incorporation of these embeddings improves downstream performance of almost every model across different drug pair scoring tasks.
  arXiv  Detail & Related papers  (2022-09-19T23:35:26Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• Modeling Pharmacological Effects with Multi-Relation Unsupervised Graph Embedding [4.999039245939572]
  We present a method based on a multi-relation unsupervised graph embedding model that learns latent representations for drugs and diseases. Once representations for drugs and diseases are obtained we learn the likelihood of new links (that is, new indications) between drugs and diseases. Known drug indications are used for learning a model that predicts potential indications.
  arXiv  Detail & Related papers  (2020-04-30T14:51:25Z)
• Drug-Drug Interaction Prediction with Wasserstein Adversarial Autoencoder-based Knowledge Graph Embeddings [22.562175708415392]
  We propose a new knowledge graph embedding framework for drug-drug interactions. In our framework, the autoencoder is employed to generate high-quality negative samples. The discriminator learns the embeddings of drugs and interactions based on both positive and negative triplets.
  arXiv  Detail & Related papers  (2020-04-15T21:03:29Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.